dr-jacque-duncan-md-105-1440x784-2x
dr-jacque-duncan-md-105-320x320-2x

Jacque L. Duncan

MD

Ophthalmologist
Vitreoretinal surgeon
Loves dog walks and eye imaging with advanced technology

Dr. Jacque Duncan is an ophthalmologist who specializes in treating retinal degenerative diseases, such as retinitis pigmentosa, which affects one in 3,500 people worldwide, and age-related macular degeneration, the leading cause of blindness in Americans over age 50. Both conditions run in families and have no cure. In addition, her expertise includes diagnosing and treating retinal diseases such as Usher syndrome (an inherited disorder that affects both vision and hearing), cone-rod dystrophy (an inherited disorder in which the retina's light-sensitive cells deteriorate) and Stargardt disease (a form of macular degeneration that develops in childhood). She is skilled in using experimental techniques to prevent or slow these conditions.

In her research, Duncan is studying treatments to preserve vision as well as devices to stimulate visual perception. She has received research funding from Research to Prevent Blindness, the Karl Kirchgessner Foundation, Hope for Vision and the American Geriatrics Society, in addition to receiving a Career Development Award from the Foundation Fighting Blindness.

Duncan earned her medical degree at UCSF, where she also completed an ophthalmology residency. She then completed a medical retina fellowship at the Penn Medicine Scheie Eye Institute, where she focused on patients with age-related macular degeneration and inherited retinal degeneration. She joined the UCSF faculty in 2000.

  • Education

    UCSF School of Medicine, 1995

  • Residencies

    UCSF, Ophthalmology, 1999

  • Fellowships

    Scheie Eye Institute, Medical Retina, 2000

  • Board Certifications

    Ophthalmology, American Board of Ophthalmology

  • Academic Title

    Professor

Working with others to address major challenges enables me to help people with vision problems.

Where I see patients (1)

    Decorative Caduceus

    Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia

    Proportion of participants experiencing grade 3 or greater adverse events

    Recruiting

    More about this study
    Decorative Caduceus

    Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia

    Proportion of participants experiencing grade 3 or greater adverse events

    Recruiting

    More about this study
    Decorative Caduceus

    Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F

    measured by static perimetry with quantitative, topographic analysis (Hill of Vision) and assessed by a central reading center

    Recruiting

    More about this study
    Decorative Caduceus

    Retinal Imaging in Patients With Inherited Retinal Degenerations

    The current study will assess cone spacing twice at baseline and every 6 months for 30 months. The primary outcome will be measured at 24 months.

    Recruiting

    More about this study
    See all clinical trials

    Saving future lives

    500+ UCSF investigators are researching cures for hundreds of childhood and adult diseases.

    Share